The EPMRC was one of the most informative, thought-provoking and insightful conferences that I have attended for several years. I recommend EPMRC as a must attend to all those in market research and decision support roles across Europe.
Loading - Please wait
It doesn’t matter how fast your strategy advances, there’s always a gap that makes your competitors move faster. Digital acceleration and massive demographics define an era where every business is in the business of interaction and experiences. You are not a pharma manufacturer, you are a pharma services company. Learn about how to use people as newness sensors to identify opportunities that will lead your company into a better competitive landscape. We cannot predict the future, but if we observe every detail shaping the present, we can invent it and we can lead it.
· Partnership as key element – forms of investment and co-development
· New incubation model for Europe
an innovative biologic product to transform itself from a traditional pill/potion/patch company to a biologics/scientific/specialty oriented company.
Prevent the pitfalls associated with one-dimensional ATU-trackers: clarify the relevance of messaging to physicians.
• What do respondents think of the online experience?
• The client’s prospective
• A case study with both physicians and payers
Which patients? What type? How many? What the brand team didn’t expect was an approach that captured prescribing intent with such precision that it turned round conventional thinking and elevated a ‘simple forecast’ to a robust, compelling evidence base for a winning strategic direction. Powering fresh momentum, confident decisions, more impactful customer engagement and better informed physicians, the ‘in-the-moment’ clarity of mobile forecasting proved the albeit unanticipated driving force that ensured a successful launch.
• How can you reveal normalisation to the patient so they ‘see’ it and communicate their experience of a disease or treatment more accurately?
• How can you address normalisation to in a way such that patients get and stay on track with treatment?
• How can you know that normalisation is taking place if patients themselves can’t see it?
Normalisation leads to under-reporting by patients of the clinical burden of disease and is one of the biggest challenges we face in customer insight research. It leads to disconnection in patient-HCP interactions, undermines compliance and persistence and makes it hard for patients to identify their unmet needs. Getting to understand patients better from early stage by unravelling normalisation and its consequences is invaluable in the push for improvement in treatment, devices and new formulations.
Four pharma-hosted diabetes websites in the German-speaking area were explored in a representative online survey with 90 patients suffering from Diabetes type I or II. In addition to explicit survey data, implicit, physiological measures were employed in order to reveal what patients cannot express or talk about a. A number of best practices are derived that help to create information websites that really fit users’ needs and therefore foster the market success of your brand.
– Presentation of process & essentials to set up a market intelligence organization
– Key areas to focus on initially
– Value of using an established framework
Originally developed for consumer market research on choice processes conducted in the 1970’s, process tracing investigates the steps physicians take to acquire information about their patients, as well as their ultimate diagnosis or treatment decisions. This presentation shows how process tracing methods can be used in qualitative and quantitative market research to identify the treatment algorithms that physicians and other healthcare providers actually use in their practices.
Increasingly, these are the coin of the realm when it comes to informing, engaging and enlightening audiences of all kinds. This talk looks at how the power of motion picture is being applied today to the capture and dissemination of market research insights.
Using automated oligosaccharide synthesis and continuous chemistry as examples, this presentation will show how fundamental advances in science have resulted in novel vaccines and efficient processes for active pharmaceutical ingredient production. The breakthroughs have been patented and resulted in spin-off companies in Germany that garnered significant funding.
• How can CI add to a MR project: when a hybrid CI + MR project could be a good choice
• Designing a hybrid project: either concurrent or sequential research
• Survey results from those that work with both CI and MR